Revelation Biosciences Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Revelation Biosciences has been growing earnings at an average annual rate of 17.3%, while the Biotechs industry saw earnings growing at 19% annually.
Belangrijke informatie
17.3%
Groei van de winst
-235.3%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | n/a |
| Rendement op eigen vermogen | -1,394.4% |
| Nettomarge | n/a |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Revelation Biosciences surges 46% on licensing deal with Vanderbilt University
Oct 06Revelation Biosciences GAAP EPS of -$0.12
Aug 15Revelation Biosciences stock slides 47% on pricing $5M securities offering
Jul 26Revelation Biosciences: Therapeutics And Diagnostics For Respiratory Viral Infections
Mar 28Opbrengsten en kosten
Hoe Revelation Biosciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -16 | 5 | 5 |
| 31 Mar 24 | 0 | -9 | 5 | 4 |
| 31 Dec 23 | 0 | 0 | 5 | 4 |
| 30 Sep 23 | 0 | 1 | 4 | 3 |
| 30 Jun 23 | 0 | 2 | 4 | 2 |
| 31 Mar 23 | 0 | 2 | 4 | 2 |
| 31 Dec 22 | 0 | -11 | 5 | 5 |
| 30 Sep 22 | 0 | -13 | 6 | 8 |
| 30 Jun 22 | 0 | -15 | 6 | 9 |
| 31 Mar 22 | 0 | -16 | 7 | 9 |
| 31 Dec 21 | 0 | -12 | 5 | 7 |
| 30 Sep 21 | 0 | -11 | 5 | 6 |
Kwaliteitswinsten: REVB is currently unprofitable.
Groeiende winstmarge: REVB is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: REVB is unprofitable, but has reduced losses over the past 5 years at a rate of 17.3% per year.
Versnelling van de groei: Unable to compare REVB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: REVB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: REVB has a negative Return on Equity (-1394.44%), as it is currently unprofitable.